Latest abdominal pain Stories
CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein...
NEW YORK, Oct. 30, 2012 /PRNewswire/ -- The Jeffrey Epstein VI Foundation has backed the largest collaborative study of Crohn's and Colitis Disease in children. The study, called the Kids Pediatric Network, was initiated by the Crohn's and Colitis Foundation of America. The Jeffrey Epstein VI Foundation was founded by the prominent science philanthropist, Jeffrey Epstein in 2000. The foundation is known to support cutting edge scientific research around the world and financed the...
Study demonstrates association, not causation, researchers say Patients with chronic constipation may be at increased risk of developing colorectal cancer and benign neoplasms, according to study findings unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas. The study, "Risk of Developing Colorectal Cancer and Benign Neoplasm in Patients with Chronic Constipation," investigated the prevalence and incidence of colorectal cancer...
Provide new insights on Infliximab use, disease characteristics, fistulizing Crohn's disease Three separate studies presented today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas help to advance understanding of the differences between African American and Caucasian patients with Inflammatory Bowel Disease (IBD) and provide clinicians with new insight on how racial disparities involving disease characteristics, infliximab use, and...
SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, will present five abstracts at the American College of Gastroenterology 2012 Scientific Meeting taking place this week in Las Vegas, NV. These data add to the compelling body of evidence that supports standardized use of liquid phase assays in helping to identify potential causes for loss of treatment response among inflammatory bowel disease (IBD) patients...
LAS VEGAS, Oct. 22, 2012 /PRNewswire/ -- New Phase 3 study findings showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with subcutaneously administered SIMPONI(®) (golimumab) maintained clinical response through week 54, the primary endpoint of the study, compared with patients receiving placebo. Investigators will report clinical response, clinical remission and mucosal healing results through one year...
ATLANTA, Oct. 18, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neuroscience treatment and research, is marking the 2012 American College of Gastroenterology (ACG) Annual Scientific meeting in Las Vegas, Nevada by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's ACG meeting, October 19-24. "The annual ACG meeting gives UCB the opportunity to demonstrate our...
Synechion, Inc., a research and consulting company specializing in the prevention of adhesions - internal scars causing pain and other complications - has announced the formation of a new company, KevMed, LLC to commercialize break-through innovations for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain with very few effective treatment options currently available. Dallas, TX, (PRWEB) October 10, 2012...
SAN DIEGO, Oct. 8, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing rescue therapies for patients in ischemic crisis, today announced the completion of patient enrollment in its Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment in severely injured trauma patients experiencing hemorrhagic shock. MP4OX is a novel ischemic rescue therapy designed to improve perfusion and oxygen delivery to tissues. (Logo:...
G-Tech has obtained IRB approval to launch a clinical research study designed to record abnormal myoelectrical activity in subjects with irritable bowel syndrome (IBS). Palo Alto, Calif. (PRWEB) September 28, 2012 G-Tech, an early stage medical device company, announced today that it has received IRB approval to launch a six-month, 60-subject clinical research study designed to record abnormal myoelectrical activity in subjects with abdominal pain associated with irritable bowel syndrome...
